ERBB2 and breast cancer: In the GSE61594 dataset, survival analysis of the risk score in different breast cancer subtypes revealed that in Human Epidermal Growth Factor Receptor 2 (HER2)-positive and Triple-Negative Breast Cancer (TNBC) subtypes, high-risk breast cancer samples had poorer overall survival compared to low-risk samples (Figures 3G, H).